Joachim Listing

Joachim Listing

Auto-generated profile, based on publicly available information

Joachim Listing

German Rheumatism Research Centre, Berlin, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2005 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
JLJoachim Listing
Joachim Listing
ASAnja Strangfeld
Anja Strangfeld
SKSonja Kary
Sonja Kary
RRRolf Rau
Rolf Rau
UHUlrich von Hinueber
Ulrich von Hinueber
AZAngela Zink
Angela Zink

28 November 2012 in Rheumatology
Verified
Journal Article
Open access
PDF file
JLJoachim Listing
Joachim Listing
KGKerstin Gerhold
Kerstin Gerhold
AZAngela Zink
Angela Zink
RA is known to be associated with an increased risk of serious infection. Even more than 50 years ago, observational studies showed a greater than 2-fold increased risk of serious infection in RA. This was reinforced by various subsequent cohort studies. The elevated susceptibility of patients with RA can be explained by the pathobiology of the disease itself, the impact of chronic comorbid conditions, as well as sequelae of immunosuppressive treatment. It has been suggested that premature ageing of the immune system in RA contributes to weakened protection against infectious organisms. In addition, chronic comorbid conditions such as diabetes or chronic lung or kidney disease, disease-related functional disability, as well as lifestyle factors such as smoking, increase the risk in individual patients. For a long time glucocorticoids (GCs) have been used as potent immunosuppressive drugs in RA. There is evidence that they increase the risk of serious infections up to 4-fold in a dose-dependent manner. TNF-α inhibitors increase the serious infection risk up to 2-fold. They have, however, the potential to outweigh their risk when higher GC doses can be tapered down. If patients need higher dosages of GCs in addition to treatment with biologic agents, their risk of infection is substantial. This combination should be used carefully and, if possible, avoided in patients with additional risk factors such as older age or comorbid conditions.

1 February 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JLJoachim Listing
Joachim Listing
JKJörn Kekow
Jörn Kekow
BMBernhard Manger
Bernhard Manger
GBGerd-Rüdiger Burmester
Gerd-Rüdiger Burmester
DPDagmar Pattloch
Dagmar Pattloch
ASAnja Strangfeld
Anja Strangfeld
Objectives To investigate the impact of disease activity, the course of the disease, its treatment over time, comorbidities and traditional risk factors on survival. Methods Data of the German biologics register RABBIT were used. Cox regression was applied to investigate the impact of time-varying covariates (disease activity as measured by the DAS28, functional capacity, treatment with glucocorticoids, biologic or synthetic disease modifying antirheumatic drugs (DMARDs)) on mortality after adjustment for age, sex, comorbid conditions and smoking. Results During 31 378 patient-years of follow-up, 463 of 8908 patients died (standardised mortality ratio: 1.49 (95% CI 1.36 to 1.63)). Patients with persistent, highly active disease (mean DAS28 > 5.1) had a significantly higher mortality risk (adjusted HR (HRadj)=2.43; (95% CI 1.64 to 3.61)) than patients with persistently low disease activity (mean DAS28 < 3.2). Poor function and treatment with glucocorticoids > 5 mg/d was significantly associated with an increased mortality, independent of disease activity. Significantly lower mortality was observed in patients treated with tumour necrosis factor α (TNFα) inhibitors (HRadj=0.64 (95% CI 0.50 to 0.81), rituximab (HRadj=0.57 (95% CI 0.39 to 0.84), or other biologics (HRadj=0.64 (95% CI 0.42 to 0.99), compared to those receiving methotrexate. To account for treatment termination in patients at risk, an HRadj for patients ever exposed to TNFα inhibitors or rituximab was calculated. This resulted in an HRadj of 0.77 (95% CI 0.60 to 0.97). Conclusions Patients with long-standing high disease activity are at substantially increased risk of mortality. Effective control of disease activity decreases mortality. TNFα inhibitors and rituximab seem to be superior to conventional DMARDs in reducing this risk.

8 January 2010 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ASAnja Strangfeld
Anja Strangfeld
FHFranka Hierse
Franka Hierse
RRRolf Rau
Rolf Rau
GBGerd Ruediger Burmester
Gerd Ruediger Burmester
BKBrigitte Krummel-Lorenz
Brigitte Krummel-Lorenz
AZAngela Zink
Angela Zink
Introduction: We used the data of the German biologics register RABBIT, a nationwide prospective cohort study, to investigate the risk of new or recurrent malignancy in patients with rheumatoid arthritis (RA) receiving biologics compared to conventional disease modifying anti-rheumatic drugs (DMARDs). Methods: The analysis was based on patients with RA enrolled in RABBIT at the start of a biologic or conventional DMARD therapy between 01 May 2001 and 31 December 2006. Incidences of first or recurrent malignancies were analysed separately. A nested case-control design was used to investigate the risk of developing a first malignancy. Matching criteria were: age, gender, follow-up time, disease activity score based on 28 joint counts (DAS28) at study entry, smoking status, and selected chronic co-morbid conditions (obstructive or other lung disease, kidney, liver or gastrointestinal disease, psoriasis). Results: A prior malignancy was reported in 122 out of 5,120 patients. Fifty-eight of these patients had received anti-TNFα agents, 9 anakinra, and 55 conventional DMARDs at study entry. In 14 patients (ever exposed to anti-TNFα: eight, to anakinra: one) 15 recurrent cancers were observed. The average time period since the onset of the first malignancy was nine years. Crude recurrence rates per 1,000 patient-years (pyrs) were 45.5 for patients exposed to anti-TNFα agents, 32.3 for anakinra patients and 31.4 for patients exposed to DMARDs only (Incidence rate ratio anti-TNFα vs. DMARD = 1.4, P = 0.6.). In patients without prior cancer, 74 patients (70% female, mean age: 61.3) developed a first malignancy during the observation. This corresponds to an incidence rate (IR) of 6.0/1,000 pyrs. Forty-four of these patients were ever exposed to anti-TNFα treatment (IR = 5.1/1,000 pyrs). In a nested case-control study comparing cancer patients to cancer-free controls, 44 of the cancer patients and 44 of the cancer-free controls were ever exposed to anti-TNFα agents (P = 1.0). Conclusions: No significant differences in the overall incidence of malignancies in patients exposed or unexposed to anti-TNFα or anakinra treatment were found. The same applied to the risk of recurrent malignancies. However, in particular this last finding needs further validation in larger data sets.

29 February 2008 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JLJoachim Listing
Joachim Listing
ASAnja Strangfeld
Anja Strangfeld
JKJörn Kekow
Jörn Kekow
MSMatthias Schneider
Matthias Schneider
AKAndreas Kapelle
Andreas Kapelle
AZAngela Zink
Angela Zink
Objective: To determine the hazard risk of developing or worsening heart failure in rheumatoid arthritis (RA) patients treated with tumor necrosis factor α (TNFα) inhibitors.Methods: RA patients ages 18–75 years who started treatment with infliximab, etanercept, or adalimumab (n = 2,757), or conventional disease‐modifying antirheumatic drugs (controls; n = 1,491) at the time of enrollment in a German biologics register were studied. Cox proportional hazards models were applied to investigate the influence of disease‐related and treatment‐specific risk factors on the incidence or worsening of heart failure.Results: The 3‐year incidence rates of heart failure in patients with and patients without cardiovascular disease at the start of treatment were 2.2% and 0.4%, respectively. After adjustment for traditional cardiovascular risk factors, an increased risk of developing heart failure was found in patients who had a higher 28‐joint Disease Activity Score at followup (hazard ratio [HR] 1.47 [95% confidence interval 1.07–2.02], P = 0.019). A residual nonsignificant risk related to treatment with TNFα inhibitors remained (adjusted HR 1.66 [95% confidence interval 0.67–4.1], P = 0.28). This residual risk was balanced by the efficacy of the anti‐TNF treatment. When only baseline characteristics were taken into account, the HR related to TNFα inhibitor treatment decreased to 0.70 (95% confidence interval 0.27–1.84).Conclusion: The findings of this study indicate that TNFα inhibitor treatment that effectively reduces the inflammatory activity of RA is more likely to be beneficial than harmful with regard to the risk of heart failure, especially if there is no concomitant therapy with glucocorticoids or cyclooxygenase 2 inhibitors. Furthermore, the data suggest that TNFα inhibition does not increase the risk of worsening of prevalent heart failure.

1 February 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LMLouise K Mercer
Louise K Mercer
JAJohan Askling
Johan Askling
PRPauline Raaschou
Pauline Raaschou
WDWilliam G Dixon
William G Dixon
LDLene Dreyer
Lene Dreyer
JLJoachim Listing
Joachim Listing
Objectives Some studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The aim of this study was to investigate the incidence of invasive cutaneous melanomas in patients with rheumatoid arthritis (RA) treated with TNF inhibitors (TNFi), other biologic disease modifying drugs and non-biologic therapy. Methods Eleven biologic registers from nine European countries participated in this collaborative project. According to predefined exposure definitions, cohorts of patients with RA were selected. Using the country-specific general population of each register as reference, age, sex and calendar year standardised incidence ratios (SIRs) of invasive histology-confirmed cutaneous melanoma were calculated within each register. Pooled SIR and incidence rate ratios (IRRs) comparing biologic cohorts to biologic-naïve were calculated across countries by taking the size of the register into account. Results Overall 130 315 RA patients with a mean age of 58 years contributing 579 983 person-years were available for the analysis and 287 developed a first melanoma. Pooled SIRs for biologic-naïve, TNFi and rituximab-exposed patients were 1.1 (95% CI 0.9 to 1.4), 1.2 (0.99 to 1.6) and 1.3 (0.6 to 2.6), respectively. Incidence rates in tocilizumab and abatacept-exposed patients were also not significantly increased. IRR versus biologic-naïve patients were: TNFi 1.1 (95% CI 0.8 to 1.6); rituximab 1.2 (0.5 to 2.9). Conclusions This large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi.